Sihuan Pharmaceutical (00460) announced interim results, profit attributable to shareholders of 225 million yuan, increased 119% year-on-year, and continued to anchor the “Medical+Innovative Drug” two-wheel drive medium- and long-term development strategy

According to the Zhitong Finance App, Sihuan Pharmaceutical (00460) announced results for the six months ended June 30, 2026. The group achieved total revenue of 1,161 million yuan during the period, an increase of 1.3% over the previous year; profit attributable to company owners was 225 million yuan, an increase of 119 percent over the previous year; basic profit per share was 2.49 points.

According to the announcement, changes in earnings are mainly driven by the medical, aesthetic and innovative drug businesses. During the period, revenue from the medical and aesthetic business was approximately RMB 693 million (6 months ended June 30, 2025: RMB 585 million), an increase of approximately 18.5% over the previous year. The medical and aesthetic business has maintained steady development. The Group's medical and aesthetic sector continues to benefit from the steady growth of the core product Lotivo ^® (botulinum toxin), as well as the continued release of regenerative medical and aesthetic products (including beauty acupuncture and teenage acupuncture) and functional medical and aesthetic products, driving related business revenue growth. The medical and aesthetic business continues to be an important source of profit for the Group.

Revenue from innovative drugs and other pharmaceuticals was approximately RMB 261 million (6 months ended June 30, 2025: RMB 58.2 million), an increase of approximately 349.1% over the previous year. The commercialization process of the innovative drug business continues to advance. The commercialization and internationalization of various approved products progressed well, and consolidated revenue ushered in a significant increase. Compared with the net loss of the previous period, net profit for the current period increased slightly.

In the first half of 2026, the Group continued to anchor the “Medical+Aesthetic+Innovative Drug” two-wheel drive medium- and long-term development strategy. The overall operating fundamentals continued to improve, profit optimization logic continued to be implemented, and AI R&D empowerment, global layout and multi-level capital operation were simultaneously promoted, and the foundation for medium- to long-term value growth was further consolidated.